The details bedevil DCOR.
Calcium-free oral phosphorus binders were heralded as a striking new development for patients with chronic kidney disease, promising a reduction in morbidity and mortality from cardiovascular disease. Sevelamer hydrochloride was the first such drug introduced to the market. Dialysis Clinical Outcomes Revisited (DCOR) is an outcomes study on the effect of sevelamer compared with calcium-based phosphorus binders in dialysis patients. It does not show a clear superiority of one compound over the other.
Silver
J
J
Minerva Center for Calcium and Bone Metabolism, Nephrology and Hypertension Services, Hadassah Hebrew University Medical Center, Jerusalem, Israel. silver@huji.ac.il
D000367:Age Factors; D002118:Calcium / Q000097:blood; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002614:Chelating Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000628:therapy*; D010758:Phosphorus / Q000097:blood; D011073:Polyamines / Q000627:therapeutic use*; D006435:Renal Dialysis; D000069603:Sevelamer; D016896:Treatment Outcome
D002614:Chelating Agents; D011073:Polyamines; D010758:Phosphorus; D000069603:Sevelamer; D002118:Calcium